Article(id=1329529324471955907, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329529184759689798, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2024.08.016, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1713715200000, receivedDateStr=2024-04-22, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794914092413, onlineDateStr=2026-11-17, pubDate=1723219200000, pubDateStr=2024-08-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794914092413, onlineIssueDateStr=2026-11-17, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794914092413, creator=13701087609, updateTime=1794914092413, updator=13701087609, issue=Issue{id=1329529184759689798, tenantId=1146029695717560320, journalId=1319690329412173987, year='2024', volume='45', issue='8', pageStart='803', pageEnd='902', issueExtLink='null', onlineDate='null', pubDate='1723219200000', pubDateStr='2024-08-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794914059104, creator='13701087609', updateTime=1794962181451, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329731024885494053, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329529184759689798, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329731024885494054, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329529184759689798, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=897, endPage=902, ext={EN=ArticleExt(id=1329529324723614148, articleId=1329529324471955907, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Research progress on new drugs for primary immune thrombocytopenia, columnId=1325221194584162830, journalTitle=World Clinical Drug, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

Primary immune thrombocytopenia (ITP) is an autoimmune disease characterized by increased platelet destruction and inadequate megakaryocyte maturation. In recent years, with the in-depth study of the pathogenesis of ITP, new drugs related to spleen tyrosine kinase, Bruton's tyrosine kinase, neonatal Fc receptor inhibitors, platelet desialylation, B-cell activating factor and classical complement pathway have gradually become the focus of ITP treatment. This article reviewed the research progress on new ITP drugs in recent years, aiming to provide reference for selecting appropriate individualized treatment according to the pathogenesis and economic situation in the future.

, authors=Hanchun WANG1, Juan CHENG1, 2, 3, *, authorsList=Hanchun WANG, Juan CHENG, authorCompany=null, correspAuthors=Juan CHENG, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329529325134655941, articleId=1329529324471955907, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=原发免疫性血小板减少症新药治疗研究进展, columnId=1325221194743546384, journalTitle=世界临床药物, columnName=综述评论, runingTitle=null, highlight=null, articleAbstract=

原发免疫性血小板减少症(primary immune thrombocytopenia,ITP)是一种自身免疫性疾病,其特征为血小板破坏增加和巨核细胞成熟不足。近年来,随着对ITP发病机制的深入研究,脾酪氨酸激酶、布鲁顿酪氨酸激酶、新生儿Fc受体抑制剂、血小板去唾液酸化、B细胞活化因子和经典补体途径相关新药逐渐成为ITP治疗的热点。现就近年来ITP新药研究进展作综述,旨在为今后根据发病机制、经济情况等选择合适的个体化治疗方案提供参考。

, authors=王晗纯1, 成娟1, 2, 3, *, authorsList=王晗纯, 成娟, authorCompany=null, correspAuthors=成娟, authorNote=

王晗纯,硕士研究生,研究方向:血液系统疾病诊疗。

, correspAuthorsNote=
成娟,主任医师,博士生导师,研究方向:血液系统疾病诊疗。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=T8TKqiIuV6AevjKIeCMMaQ==, magXml=PIVrM8661qIRhb8DB0HSng==, pdfUrl=null, pdf=36aA5XnfKUlbGMikB/c/jg==, pdfFileSize=1578129, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=IfDGDfNNUlOcOiWHeQ7OeQ==, mapNumber=null, fund=null)}, authors=[Author(id=1329529327319888336, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329529327454106066, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, authorId=1329529327319888336, language=EN, stringName=Hanchun WANG, firstName=Hanchun, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.First School of Clinical Medicine of Lanzhou University, Lanzhou 730000, Gansu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329529327563157971, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, authorId=1329529327319888336, language=CN, stringName=王晗纯, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.兰州大学第一临床医学院,甘肃 兰州 730000, bio={"content":"

王晗纯,硕士研究生,研究方向:血液系统疾病诊疗。

"}, bioImg=null, bioContent=

王晗纯,硕士研究生,研究方向:血液系统疾病诊疗。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329529325386314182, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, xref=1., ext=[AuthorCompanyExt(id=1329529325398897095, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, companyId=1329529325386314182, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.First School of Clinical Medicine of Lanzhou University, Lanzhou 730000, Gansu Province, China), AuthorCompanyExt(id=1329529325407285704, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, companyId=1329529325386314182, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.兰州大学第一临床医学院,甘肃 兰州 730000)])]), Author(id=1329529327672209877, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329529327793844697, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, authorId=1329529327672209877, language=EN, stringName=Juan CHENG, firstName=Juan, middleName=null, lastName=CHENG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, 3, *, address=1.First School of Clinical Medicine of Lanzhou University, Lanzhou 730000, Gansu Province, China
2.Department of Hematology, the First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China
3.Department of Hematology, Donggang Branch of the First Hospital of Lanzhou University, Lanzhou 730022, Gansu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329529327860953562, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, authorId=1329529327672209877, language=CN, stringName=成娟, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, 3, *, address=1.兰州大学第一临床医学院,甘肃 兰州 730000
2.兰州大学第一医院血液科,甘肃 兰州 730000
3.兰州大学第一医院东岗院区血液科,甘肃 兰州 730022, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329529325386314182, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, xref=1., ext=[AuthorCompanyExt(id=1329529325398897095, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, companyId=1329529325386314182, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.First School of Clinical Medicine of Lanzhou University, Lanzhou 730000, Gansu Province, China), AuthorCompanyExt(id=1329529325407285704, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, companyId=1329529325386314182, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.兰州大学第一临床医学院,甘肃 兰州 730000)]), AuthorCompany(id=1329529325491171785, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, xref=2., ext=[AuthorCompanyExt(id=1329529325499560394, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, companyId=1329529325491171785, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Hematology, the First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China), AuthorCompanyExt(id=1329529325512143307, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, companyId=1329529325491171785, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.兰州大学第一医院血液科,甘肃 兰州 730000)]), AuthorCompany(id=1329529327177281996, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, xref=3., ext=[AuthorCompanyExt(id=1329529327202447821, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, companyId=1329529327177281996, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Department of Hematology, Donggang Branch of the First Hospital of Lanzhou University, Lanzhou 730022, Gansu Province, China), AuthorCompanyExt(id=1329529327215030734, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, companyId=1329529327177281996, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.兰州大学第一医院东岗院区血液科,甘肃 兰州 730022)])])], keywords=[Keyword(id=1329529328007754203, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, language=EN, orderNo=1, keyword=primary immune thrombocytopenia), Keyword(id=1329529328091640284, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, language=EN, orderNo=2, keyword=tyrosinase inhibitor), Keyword(id=1329529328171332061, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, language=EN, orderNo=3, keyword=neonatal Fc receptor inhibitor), Keyword(id=1329529328251023838, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, language=EN, orderNo=4, keyword=B-cell activating factor inhibitor), Keyword(id=1329529328347492831, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, language=EN, orderNo=5, keyword=complement inhibitor), Keyword(id=1329529328443961824, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, language=CN, orderNo=1, keyword=原发免疫性血小板减少), Keyword(id=1329529328511070689, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, language=CN, orderNo=2, keyword=酪氨酸酶抑制剂), Keyword(id=1329529328603345378, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, language=CN, orderNo=3, keyword=新生儿Fc受体抑制剂), Keyword(id=1329529328666259939, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, language=CN, orderNo=4, keyword=B细胞活化因子抑制剂), Keyword(id=1329529328724980196, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, language=CN, orderNo=5, keyword=补体抑制剂)], refs=[Reference(id=1329529328825643493, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Lv Y, Shi H, Liu H, et al. Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?[J]. Front Immunol, 2022, 13: 953716., articleTitle=null, refAbstract=null), Reference(id=1329529328888558054, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Madkhali MA. Recent advances in the management of immune thrombocytopenic purpura (ITP): a comprehensive review[J]. Medicine (Baltimore), 2024, 103(3): e36936., articleTitle=null, refAbstract=null), Reference(id=1329529328980832743, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Mititelu A, Onisâi MC, Roșca A, et al. Current understanding of immune thrombocytopenia: a review of pathogenesis and treatment options[J]. Int J Mol Sci, 2024, 25(4): 2163., articleTitle=null, refAbstract=null), Reference(id=1329529329056330216, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Zaja F, Carpenedo M, Baratè C, et al. Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: real-world recommendations[J]. Blood Rev, 2020, 41: 100647., articleTitle=null, refAbstract=null), Reference(id=1329529329127633385, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Delshad M, Davoodi-Moghaddam Z, Pourbagheri-Sigaroodi A, et al. Translating mechanisms into therapeutic strategies for immune thrombocytopenia (ITP): lessons from clinical trials[J]. Thromb Res, 2024, 235: 125-147., articleTitle=null, refAbstract=null), Reference(id=1329529329182159338, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Al-Samkari H, Jiang D, Gernsheimer T, et al. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: a multicentre US study[J]. Br J Haematol, 2022, 197(3): 359-366., articleTitle=null, refAbstract=null), Reference(id=1329529329249268203, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Schifferli A, Rüfer A, Rovo A, et al. Immunomodulation with romiplostim as a second-line strategy in primary immune thrombocytopenia: the iROM study[J]. Br J Haematol, 2023, 203(1): 119-130., articleTitle=null, refAbstract=null), Reference(id=1329529329362514412, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Wong A, Ahuja T, Cirrone F, et al. Antithrombotic and hemostatic stewardship: evaluation of romiplostim for treatment of thrombocytopenia at a large academic medical center[J]. J Oncol Pharm Pract, 2024, 30(2): 246-250., articleTitle=null, refAbstract=null), Reference(id=1329529329442206189, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Grainger J, Bussel J, Tarantino M, et al. A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia[J]. Blood Adv, 2023, 7(3): 396-405., articleTitle=null, refAbstract=null), Reference(id=1329529329526092270, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Reiser M, Josten KM, Dietzfelbinger H, et al. Romiplostim for primary immune thrombocytopenia in routine clinical practice: results from a multicentre observational study in Germany[J]. Acta Haematol, 2022, 145(4): 394-403., articleTitle=null, refAbstract=null), Reference(id=1329529329593201135, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhou H, Zhou J, Wu D, et al. Romiplostim in primary immune thrombocytopenia that is persistent or chronic: phase Ⅲ multicenter, randomized, placebo-controlled clinical trial in China[J]. Res Pract Thromb Haemost, 2023, 7(5): 100192., articleTitle=null, refAbstract=null), Reference(id=1329529329660310000, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Yassin MA, Al-Rasheed M, Al-Khaboori M, et al. Thrombopoietin-receptor agonists for adult patients with immune thrombocytopenia: a narrative review and an approach for managing patients fasting intermittently[J]. Front Cardiovasc Med, 2023, 10: 1260487., articleTitle=null, refAbstract=null), Reference(id=1329529329735807473, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=程文迪, 罗雅双, 符雨嫣, 等. 罗普司亭治疗成人原发免疫性血小板减少症的经济学评价系统综述[J]. 中国合理用药探索, 2023, 20(6): 77-86., articleTitle=null, refAbstract=null), Reference(id=1329529329844859378, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Auteri G, Biondo M, Mazzoni C, et al. Sustained response off therapy after fostamatinib: a chronic refractory ITP case report[J]. Heliyon, 2023, 9(2): e13462., articleTitle=null, refAbstract=null), Reference(id=1329529329928745459, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Matsukane R, Suetsugu K, Hirota T, et al. Clinical pharmacokinetics and pharmacodynamics of fostamatinib and its active moiety R406[J]. Clin Pharmacokinet, 2022, 61(7): 955-972., articleTitle=null, refAbstract=null), Reference(id=1329529330021020148, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials[J]. Am J Hematol, 2018, 93(7): 921-930., articleTitle=null, refAbstract=null), Reference(id=1329529331245756917, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Kuwana M, Ito T, Kowata S, et al. Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: a phase 3, placebo-controlled, double-blind, parallel-group study[J]. Br J Haematol, 2023, 200(6): 802-811., articleTitle=null, refAbstract=null), Reference(id=1329529331384168950, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Liu X, Zhou H, Hu Y, et al. Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study[J]. Lancet Haematol, 2023, 10(6): e406-e418., articleTitle=null, refAbstract=null), Reference(id=1329529331472249335, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Owens TD, Brameld KA, Verner EJ, et al. Discovery of reversible covalent Bruton's tyrosine kinase inhibitors PRN473 and PRN1008 (rilzabrutinib)[J]. J Med Chem, 2022, 65(7): 5300-5316., articleTitle=null, refAbstract=null), Reference(id=1329529331572912632, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Von Hundelshausen P, Siess W. Bleeding by Bruton tyrosine kinase-inhibitors: dependency on drug type and disease[J]. Cancers (Basel), 2021, 13(5): 1103., articleTitle=null, refAbstract=null), Reference(id=1329529331669381625, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Ucpinar S, Darpo B, Neale A, et al. A thorough QTc study to evaluate the effects of oral rilzabrutinib administered alone and with ritonavir in healthy subjects[J]. Clin Transl Sci, 2022, 15(6): 1507-1518., articleTitle=null, refAbstract=null), Reference(id=1329529331732296186, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Kuter DJ, Efraim M, Mayer J, et al. Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia[J]. N Engl J Med, 2022, 386(15): 1421-1431., articleTitle=null, refAbstract=null), Reference(id=1329529331799405051, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Kuter DJ, Bussel JB, Ghanima W, et al. Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase Ⅲ study[J]. Ther Adv Hematol, 2023, 14: 20406207231205431., articleTitle=null, refAbstract=null), Reference(id=1329529331870708220, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Dhillon S. Orelabrutinib: first approval[J]. Drugs, 2021, 81(4): 503-507., articleTitle=null, refAbstract=null), Reference(id=1329529332021703165, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Lledo-Garcia R, Dixon K, Shock A, et al. Pharmacokinetic-pharmacodynamic modelling of the anti-FcRn monoclonal antibody rozanolixizumab: translation from preclinical stages to the clinic[J]. CPT Pharmacometrics Syst Pharmacol, 2022, 11(1): 116-128., articleTitle=null, refAbstract=null), Reference(id=1329529332143337982, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Robak T, Kaźmierczak M, Jarque I, et al. Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia[J]. Blood Adv, 2020, 4(17): 4136-4146., articleTitle=null, refAbstract=null), Reference(id=1329529332239806975, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Newland AC, Sánchez-González B, Rejtő L, et al. Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia[J]. Am J Hematol, 2020, 95(2): 178-187., articleTitle=null, refAbstract=null), Reference(id=1329529332294332928, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Heo YA. Efgartigimod: first approval[J]. Drugs, 2022, 82(3): 341-348., articleTitle=null, refAbstract=null), Reference(id=1329529332357247489, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Broome CM, McDonald V, Miyakawa Y, et al. Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE Ⅳ): a multicentre, randomised, placebo-controlled, phase 3 trial[J]. Lancet, 2023, 402(10413): 1648-1659., articleTitle=null, refAbstract=null), Reference(id=1329529332420162050, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=Colunga-Pedraza PR, Peña-Lozano SP, Sánchez-Rendón E, et al. Oseltamivir as rescue therapy for persistent, chronic, or refractory immune thrombocytopenia: a case series and review of the literature[J]. J Thromb Thrombolysis, 2022, 54(2): 360-366., articleTitle=null, refAbstract=null), Reference(id=1329529332495659523, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Sun L, Wang J, Shao L, et al. Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial[J]. Lancet Haematol, 2021, 8(4): e289-e298., articleTitle=null, refAbstract=null), Reference(id=1329529332583739908, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=Mahévas M, Azzaoui I, Crickx E, et al. Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: results from a prospective phase 2b trial[J]. Haematologica, 2021, 106(9): 2449-2457., articleTitle=null, refAbstract=null), Reference(id=1329529332671820293, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=李会婷. 贝利尤单抗联合环孢素治疗激素难治性免疫性血小板减少症探索性研究初步结果[D]. 昆明: 昆明医科大学, 2023., articleTitle=null, refAbstract=null), Reference(id=1329529332743123462, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=Bowman SJ, Fox R, Dörner T, et al. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial[J]. Lancet, 2022, 399(10320): 161-171., articleTitle=null, refAbstract=null), Reference(id=1329529332814426631, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=Castelli R, Lambertenghi Delilliers G, Gidaro A, et al. Complement activation in patients with immune thrombocytopenic purpura according to phases of disease course[J]. Clin Exp Immunol, 2020, 201(3): 258-265., articleTitle=null, refAbstract=null), Reference(id=1329529332898312712, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=Broome CM, Röth A, Kuter DJ, et al. Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia[J]. Blood Adv, 2023, 7(6): 987-996., articleTitle=null, refAbstract=null), Reference(id=1329529333019947529, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=Xiao Z, Murakhovskaya I. Rituximab resistance in ITP and beyond[J]. Front Immunol, 2023, 14: 1215216., articleTitle=null, refAbstract=null), Reference(id=1329529333108027914, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=李福原, 张渝, 黄柳焕, 等. 慢性原发免疫性血小板减少症药物治疗研究现状[J]. 中国医学创新, 2023, 20(6): 176-181., articleTitle=null, refAbstract=null), Reference(id=1329529333183525387, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhou J, Xu Y, Shu J, et al. GPIbα CAAR-T cells function like a Trojan horse to eliminate autoreactive B cells to treat immune thrombocytopenia[J]. Haematologica, 2024, 109(7): 2256-2270., articleTitle=null, refAbstract=null), Reference(id=1329529333246439948, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=He Y, Ji D, Lu W, et al. Bone marrow mesenchymal stem cell-derived exosomes induce the Th17/Treg imbalance in immune thrombocytopenia through miR-146a-5p/IRAK1 axis[J]. Hum Cell, 2021, 34(5): 1360-1374., articleTitle=null, refAbstract=null), Reference(id=1329529333389046285, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=Audia S, Bonnotte B. Emerging therapies in immune thrombocytopenia[J]. J Clin Med, 2021, 10(5): 1004., articleTitle=null, refAbstract=null), Reference(id=1329529333527458318, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=Audia S, Mahévas M, Nivet M, et al. Immune thrombocytopenia: recent advances in pathogenesis and treatments[J]. Hemasphere, 2021, 5(6): e574., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1329529325386314182, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, xref=1., ext=[AuthorCompanyExt(id=1329529325398897095, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, companyId=1329529325386314182, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.First School of Clinical Medicine of Lanzhou University, Lanzhou 730000, Gansu Province, China), AuthorCompanyExt(id=1329529325407285704, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, companyId=1329529325386314182, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.兰州大学第一临床医学院,甘肃 兰州 730000)]), AuthorCompany(id=1329529325491171785, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, xref=2., ext=[AuthorCompanyExt(id=1329529325499560394, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, companyId=1329529325491171785, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Hematology, the First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China), AuthorCompanyExt(id=1329529325512143307, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, companyId=1329529325491171785, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.兰州大学第一医院血液科,甘肃 兰州 730000)]), AuthorCompany(id=1329529327177281996, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, xref=3., ext=[AuthorCompanyExt(id=1329529327202447821, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, companyId=1329529327177281996, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Department of Hematology, Donggang Branch of the First Hospital of Lanzhou University, Lanzhou 730022, Gansu Province, China), AuthorCompanyExt(id=1329529327215030734, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, companyId=1329529327177281996, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.兰州大学第一医院东岗院区血液科,甘肃 兰州 730022)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2024.08.016, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2024.08.016, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2024.08.016, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2024.08.016, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1723219200000, fullTextJson=null, articleText=null, reference=null)
收藏切换
原发免疫性血小板减少症新药治疗研究进展
王晗纯 1 , 成娟 1, 2, 3, *
世界临床药物 | 综述评论 2024,45(8): 897-902
收起
收藏切换
世界临床药物 |综述评论 2024 , 45 (8) : 897 -902
原发免疫性血小板减少症新药治疗研究进展
全屏
[Author(id=1329529327319888336, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329529327454106066, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, authorId=1329529327319888336, language=EN, stringName=Hanchun WANG, firstName=Hanchun, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.First School of Clinical Medicine of Lanzhou University, Lanzhou 730000, Gansu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329529327563157971, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, authorId=1329529327319888336, language=CN, stringName=王晗纯, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.兰州大学第一临床医学院,甘肃 兰州 730000, bio={"content":"

王晗纯,硕士研究生,研究方向:血液系统疾病诊疗。

"}, bioImg=null, bioContent=

王晗纯,硕士研究生,研究方向:血液系统疾病诊疗。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329529325386314182, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, xref=1., ext=[AuthorCompanyExt(id=1329529325398897095, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, companyId=1329529325386314182, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.First School of Clinical Medicine of Lanzhou University, Lanzhou 730000, Gansu Province, China), AuthorCompanyExt(id=1329529325407285704, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, companyId=1329529325386314182, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.兰州大学第一临床医学院,甘肃 兰州 730000)])]), Author(id=1329529327672209877, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329529327793844697, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, authorId=1329529327672209877, language=EN, stringName=Juan CHENG, firstName=Juan, middleName=null, lastName=CHENG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, 3, *, address=1.First School of Clinical Medicine of Lanzhou University, Lanzhou 730000, Gansu Province, China
2.Department of Hematology, the First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China
3.Department of Hematology, Donggang Branch of the First Hospital of Lanzhou University, Lanzhou 730022, Gansu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329529327860953562, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, authorId=1329529327672209877, language=CN, stringName=成娟, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, 3, *, address=1.兰州大学第一临床医学院,甘肃 兰州 730000
2.兰州大学第一医院血液科,甘肃 兰州 730000
3.兰州大学第一医院东岗院区血液科,甘肃 兰州 730022, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329529325386314182, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, xref=1., ext=[AuthorCompanyExt(id=1329529325398897095, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, companyId=1329529325386314182, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.First School of Clinical Medicine of Lanzhou University, Lanzhou 730000, Gansu Province, China), AuthorCompanyExt(id=1329529325407285704, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, companyId=1329529325386314182, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.兰州大学第一临床医学院,甘肃 兰州 730000)]), AuthorCompany(id=1329529325491171785, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, xref=2., ext=[AuthorCompanyExt(id=1329529325499560394, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, companyId=1329529325491171785, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Hematology, the First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China), AuthorCompanyExt(id=1329529325512143307, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, companyId=1329529325491171785, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.兰州大学第一医院血液科,甘肃 兰州 730000)]), AuthorCompany(id=1329529327177281996, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, xref=3., ext=[AuthorCompanyExt(id=1329529327202447821, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, companyId=1329529327177281996, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Department of Hematology, Donggang Branch of the First Hospital of Lanzhou University, Lanzhou 730022, Gansu Province, China), AuthorCompanyExt(id=1329529327215030734, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529324471955907, companyId=1329529327177281996, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.兰州大学第一医院东岗院区血液科,甘肃 兰州 730022)])])]
王晗纯1, 成娟1, 2, 3, *
作者信息
  • 1.兰州大学第一临床医学院,甘肃 兰州 730000
  • 2.兰州大学第一医院血液科,甘肃 兰州 730000
  • 3.兰州大学第一医院东岗院区血液科,甘肃 兰州 730022
通讯作者:
成娟,主任医师,博士生导师,研究方向:血液系统疾病诊疗。
作者简介:

王晗纯,硕士研究生,研究方向:血液系统疾病诊疗。

Research progress on new drugs for primary immune thrombocytopenia
Hanchun WANG1, Juan CHENG1, 2, 3, *
Affiliations
  • 1.First School of Clinical Medicine of Lanzhou University, Lanzhou 730000, Gansu Province, China
  • 2.Department of Hematology, the First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China
  • 3.Department of Hematology, Donggang Branch of the First Hospital of Lanzhou University, Lanzhou 730022, Gansu Province, China
出版时间: 2024-08-10 doi: 10.13683/j.wph.2024.08.016
文章导航
收藏切换

原发免疫性血小板减少症(primary immune thrombocytopenia,ITP)是一种自身免疫性疾病,其特征为血小板破坏增加和巨核细胞成熟不足。近年来,随着对ITP发病机制的深入研究,脾酪氨酸激酶、布鲁顿酪氨酸激酶、新生儿Fc受体抑制剂、血小板去唾液酸化、B细胞活化因子和经典补体途径相关新药逐渐成为ITP治疗的热点。现就近年来ITP新药研究进展作综述,旨在为今后根据发病机制、经济情况等选择合适的个体化治疗方案提供参考。

原发免疫性血小板减少  /  酪氨酸酶抑制剂  /  新生儿Fc受体抑制剂  /  B细胞活化因子抑制剂  /  补体抑制剂

Primary immune thrombocytopenia (ITP) is an autoimmune disease characterized by increased platelet destruction and inadequate megakaryocyte maturation. In recent years, with the in-depth study of the pathogenesis of ITP, new drugs related to spleen tyrosine kinase, Bruton's tyrosine kinase, neonatal Fc receptor inhibitors, platelet desialylation, B-cell activating factor and classical complement pathway have gradually become the focus of ITP treatment. This article reviewed the research progress on new ITP drugs in recent years, aiming to provide reference for selecting appropriate individualized treatment according to the pathogenesis and economic situation in the future.

primary immune thrombocytopenia  /  tyrosinase inhibitor  /  neonatal Fc receptor inhibitor  /  B-cell activating factor inhibitor  /  complement inhibitor
王晗纯, 成娟. 原发免疫性血小板减少症新药治疗研究进展. 世界临床药物, 2024 , 45 (8) : 897 -902 . DOI: 10.13683/j.wph.2024.08.016
Hanchun WANG, Juan CHENG. Research progress on new drugs for primary immune thrombocytopenia[J]. World Clinical Drug, 2024 , 45 (8) : 897 -902 . DOI: 10.13683/j.wph.2024.08.016

参考文献 引证文献
排序方式:
[1]
Lv Y, Shi H, Liu H, et al. Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?[J]. Front Immunol, 2022, 13: 953716.
[2]
Madkhali MA. Recent advances in the management of immune thrombocytopenic purpura (ITP): a comprehensive review[J]. Medicine (Baltimore), 2024, 103(3): e36936.
[3]
Mititelu A, Onisâi MC, Roșca A, et al. Current understanding of immune thrombocytopenia: a review of pathogenesis and treatment options[J]. Int J Mol Sci, 2024, 25(4): 2163.
[4]
Zaja F, Carpenedo M, Baratè C, et al. Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: real-world recommendations[J]. Blood Rev, 2020, 41: 100647.
[5]
Delshad M, Davoodi-Moghaddam Z, Pourbagheri-Sigaroodi A, et al. Translating mechanisms into therapeutic strategies for immune thrombocytopenia (ITP): lessons from clinical trials[J]. Thromb Res, 2024, 235: 125-147.
[6]
Al-Samkari H, Jiang D, Gernsheimer T, et al. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: a multicentre US study[J]. Br J Haematol, 2022, 197(3): 359-366.
[7]
Schifferli A, Rüfer A, Rovo A, et al. Immunomodulation with romiplostim as a second-line strategy in primary immune thrombocytopenia: the iROM study[J]. Br J Haematol, 2023, 203(1): 119-130.
[8]
Wong A, Ahuja T, Cirrone F, et al. Antithrombotic and hemostatic stewardship: evaluation of romiplostim for treatment of thrombocytopenia at a large academic medical center[J]. J Oncol Pharm Pract, 2024, 30(2): 246-250.
[9]
Grainger J, Bussel J, Tarantino M, et al. A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia[J]. Blood Adv, 2023, 7(3): 396-405.
[10]
Reiser M, Josten KM, Dietzfelbinger H, et al. Romiplostim for primary immune thrombocytopenia in routine clinical practice: results from a multicentre observational study in Germany[J]. Acta Haematol, 2022, 145(4): 394-403.
[11]
Zhou H, Zhou J, Wu D, et al. Romiplostim in primary immune thrombocytopenia that is persistent or chronic: phase Ⅲ multicenter, randomized, placebo-controlled clinical trial in China[J]. Res Pract Thromb Haemost, 2023, 7(5): 100192.
[12]
Yassin MA, Al-Rasheed M, Al-Khaboori M, et al. Thrombopoietin-receptor agonists for adult patients with immune thrombocytopenia: a narrative review and an approach for managing patients fasting intermittently[J]. Front Cardiovasc Med, 2023, 10: 1260487.
[13]
程文迪, 罗雅双, 符雨嫣, 等. 罗普司亭治疗成人原发免疫性血小板减少症的经济学评价系统综述[J]. 中国合理用药探索, 2023, 20(6): 77-86.
[14]
Auteri G, Biondo M, Mazzoni C, et al. Sustained response off therapy after fostamatinib: a chronic refractory ITP case report[J]. Heliyon, 2023, 9(2): e13462.
[15]
Matsukane R, Suetsugu K, Hirota T, et al. Clinical pharmacokinetics and pharmacodynamics of fostamatinib and its active moiety R406[J]. Clin Pharmacokinet, 2022, 61(7): 955-972.
[16]
Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials[J]. Am J Hematol, 2018, 93(7): 921-930.
[17]
Kuwana M, Ito T, Kowata S, et al. Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: a phase 3, placebo-controlled, double-blind, parallel-group study[J]. Br J Haematol, 2023, 200(6): 802-811.
[18]
Liu X, Zhou H, Hu Y, et al. Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study[J]. Lancet Haematol, 2023, 10(6): e406-e418.
[19]
Owens TD, Brameld KA, Verner EJ, et al. Discovery of reversible covalent Bruton's tyrosine kinase inhibitors PRN473 and PRN1008 (rilzabrutinib)[J]. J Med Chem, 2022, 65(7): 5300-5316.
[20]
Von Hundelshausen P, Siess W. Bleeding by Bruton tyrosine kinase-inhibitors: dependency on drug type and disease[J]. Cancers (Basel), 2021, 13(5): 1103.
[21]
Ucpinar S, Darpo B, Neale A, et al. A thorough QTc study to evaluate the effects of oral rilzabrutinib administered alone and with ritonavir in healthy subjects[J]. Clin Transl Sci, 2022, 15(6): 1507-1518.
[22]
Kuter DJ, Efraim M, Mayer J, et al. Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia[J]. N Engl J Med, 2022, 386(15): 1421-1431.
[23]
Kuter DJ, Bussel JB, Ghanima W, et al. Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase Ⅲ study[J]. Ther Adv Hematol, 2023, 14: 20406207231205431.
[24]
Dhillon S. Orelabrutinib: first approval[J]. Drugs, 2021, 81(4): 503-507.
[25]
Lledo-Garcia R, Dixon K, Shock A, et al. Pharmacokinetic-pharmacodynamic modelling of the anti-FcRn monoclonal antibody rozanolixizumab: translation from preclinical stages to the clinic[J]. CPT Pharmacometrics Syst Pharmacol, 2022, 11(1): 116-128.
[26]
Robak T, Kaźmierczak M, Jarque I, et al. Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia[J]. Blood Adv, 2020, 4(17): 4136-4146.
[27]
Newland AC, Sánchez-González B, Rejtő L, et al. Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia[J]. Am J Hematol, 2020, 95(2): 178-187.
[28]
Heo YA. Efgartigimod: first approval[J]. Drugs, 2022, 82(3): 341-348.
[29]
Broome CM, McDonald V, Miyakawa Y, et al. Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE Ⅳ): a multicentre, randomised, placebo-controlled, phase 3 trial[J]. Lancet, 2023, 402(10413): 1648-1659.
[30]
Colunga-Pedraza PR, Peña-Lozano SP, Sánchez-Rendón E, et al. Oseltamivir as rescue therapy for persistent, chronic, or refractory immune thrombocytopenia: a case series and review of the literature[J]. J Thromb Thrombolysis, 2022, 54(2): 360-366.
[31]
Sun L, Wang J, Shao L, et al. Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial[J]. Lancet Haematol, 2021, 8(4): e289-e298.
[32]
Mahévas M, Azzaoui I, Crickx E, et al. Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: results from a prospective phase 2b trial[J]. Haematologica, 2021, 106(9): 2449-2457.
[33]
李会婷. 贝利尤单抗联合环孢素治疗激素难治性免疫性血小板减少症探索性研究初步结果[D]. 昆明: 昆明医科大学, 2023.
[34]
Bowman SJ, Fox R, Dörner T, et al. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial[J]. Lancet, 2022, 399(10320): 161-171.
[35]
Castelli R, Lambertenghi Delilliers G, Gidaro A, et al. Complement activation in patients with immune thrombocytopenic purpura according to phases of disease course[J]. Clin Exp Immunol, 2020, 201(3): 258-265.
[36]
Broome CM, Röth A, Kuter DJ, et al. Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia[J]. Blood Adv, 2023, 7(6): 987-996.
[37]
Xiao Z, Murakhovskaya I. Rituximab resistance in ITP and beyond[J]. Front Immunol, 2023, 14: 1215216.
[38]
李福原, 张渝, 黄柳焕, 等. 慢性原发免疫性血小板减少症药物治疗研究现状[J]. 中国医学创新, 2023, 20(6): 176-181.
[39]
Zhou J, Xu Y, Shu J, et al. GPIbα CAAR-T cells function like a Trojan horse to eliminate autoreactive B cells to treat immune thrombocytopenia[J]. Haematologica, 2024, 109(7): 2256-2270.
[40]
He Y, Ji D, Lu W, et al. Bone marrow mesenchymal stem cell-derived exosomes induce the Th17/Treg imbalance in immune thrombocytopenia through miR-146a-5p/IRAK1 axis[J]. Hum Cell, 2021, 34(5): 1360-1374.
[41]
Audia S, Bonnotte B. Emerging therapies in immune thrombocytopenia[J]. J Clin Med, 2021, 10(5): 1004.
[42]
Audia S, Mahévas M, Nivet M, et al. Immune thrombocytopenia: recent advances in pathogenesis and treatments[J]. Hemasphere, 2021, 5(6): e574.
2024年第45卷第8期
11
2
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2024.08.016
  • 接收时间:2024-04-22
  • 首发时间:2026-11-17
  • 出版时间:2024-08-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2024-04-22
基金
作者信息
    1.兰州大学第一临床医学院,甘肃 兰州 730000
    2.兰州大学第一医院血液科,甘肃 兰州 730000
    3.兰州大学第一医院东岗院区血液科,甘肃 兰州 730022

通讯作者:

成娟,主任医师,博士生导师,研究方向:血液系统疾病诊疗。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2024.08.016
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏